 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

StockNews.com upgraded shares of Heron Therapeutics (NASDAQ:HRTX  Free Report) from a sell rating to a hold rating in a report released on Monday. Several other research firms also recently...

Heron Therapeutics (NASDAQ:HRTX) Raised to Hold at StockNews.com

Investors considering a purchase of Heron Therapeutics Inc (HRTX) stock, but cautious about paying the going market price of 1.01/share, might benefit from considering selling puts among the...

#36;1, Earn 21.7% Annualized Using Options

State Board of Administration of Florida Retirement System cut its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX  Free Report) by 79.4% during the 1st quarter, according to the company in...

State Board of Administration of Florida Retirement System Sells 157,212 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ:HRTX Get Free Report) was upgraded by analysts at StockNews.com from a sell rating to a hold rating in a research note issued on Thursday. Several other research analysts also recently issued reports on the company. Needham & Company LLC reaffirmed a buy rating and set a $...

StockNews.com Upgrades Heron Therapeutics (NASDAQ:HRTX) to Hold

StockNews.com upgraded shares of Heron Therapeutics (NASDAQ:HRTX  Free Report) from a sell rating to a hold rating in a research report released on Thursday. Several other equities research analysts have also recently commented on the company. Needham  Company LLC restated a buy rating ...

Heron Therapeutics (NASDAQ:HRTX) Raised to "Hold" at StockNews.com

Heron Therapeutics, Inc. (NASDAQ:HRTX  Free Report)  Equities researchers at Northland Capmk decreased their Q3 2023 earnings per share estimates for shares of Heron Therapeutics in a research note issued to investors on Tuesday, August 15th. Northland Capmk analyst C. Byrnes now ...

Brokers Issue Forecasts for Heron Therapeutics, Inc.'s Q3 2023 Earnings (NASDAQ:HRTX)

Heron Therapeutics, Inc. (HRTX) Q2 2023 Earnings Call Transcript

Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates PR Newswire SAN DIEGO, Aug. 14, 2023 Company is well capitalized after signing $50 million working...

Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates

Heron Therapeutics Q2 2023 Earnings Preview

Heron Therapeutics, Inc. (NASDAQ:HRTX  Get Free Report) Director Adam Morgan bought 2,486,744 shares of the stock in a transaction on Friday, July 21st. The stock was purchased at an average price of $1.37 per share, with a total value of $3,406,839.28. Following the completion of the ...

Adam Morgan Buys 2,486,744 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.

Watchers	6,802
52-Wk Low	$0.9313
52-Wk High	$4.68

Market Cap	$144.98M
Volume (M)	931,032.00
52-Wk High	$4.68
52-Wk Low	$0.9313

HRTX Heron Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals